Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,159
datasets available to search
ShareScore release 0.9.0
Dataset results
1,159 results for “covid-19 vaccine”
Framework for virtual education of COVID-19 vaccines for Mandarin-speaking learners: An educational intervention module
<p><strong>Background</strong>: In the United States, patients with limited English proficiency face significant barriers to comprehending and acting upon health-related information, particularly during the COVID-19 pandemic. The ability of health professionals to communicate COVID-19-related information to Mandarin-speaking patients has proved critical in discussions about vaccine efficacy, side effects, and post-vaccine protection.</p> <p><strong>Methods</strong>: The authors created a one-hour educational module to help Mandarin-speaking medical students better convey COVID-19 vaccine information to Mandarin-only speakers. The module is composed of an educational guide, which introduced key terminology and addressed commonly asked questions, and pre- and post-surveys. The authors recruited 59 Mandarin-speaking medical students from 31 U.S. academic medical centers, all of whom had previously completed a medical Mandarin elective. The module and surveys were distributed and completed in August 2021. Data analysis measured the change in aggregate mean for subjective five-point Likert-scale questions and change in percent accuracy for objective knowledge-based questions.</p> <p><strong>Results</strong>: The educational module significantly improved participants' subjective comfort level in discussing the COVID-19 vaccine in English and Mandarin. The largest improvement in both English and Mandarin was demonstrated in the participant's ability to explain differences between the COVID-19 vaccines, with an aggregate mean improvement of 0.39 for English and 1.48 for Mandarin. Survey respondents also demonstrated increased percent accuracy in knowledge-based objective questions in Mandarin.</p> <p><strong>Conclusions</strong>: This module provides Mandarin-learning medical students with skills to deliver reliable information to the general population and acts as a model for the continued development of educational modules for multilingual medical professionals.</p>
Global misinformation spillovers in the online vaccination debate before and during COVID-19 - ex
<p>The dataset includes all the ids of the tweets analysed in the paper "Global misinformation spillovers in the online vaccination debate before and during COVID-19", divided by lang.</p> <p>They are all the tweets containing vaccines keywords in 18 different European languages, spanning the period October 2019 - March 2021 (excluded 2020 Jan - 2020 Jun).</p> <p>Note that a large fraction of the tweets can't be retrieved because of the suspension of the accounts and the removal of the posts by the users, so the study is only partially reproducible.</p> <p>The unzipped dataset has a dimension of 8,0G.</p> <p>The authors of the paper are: Lenti J, Mejova Y, Kalimeri K, Panisson A, Paolotti D, Tizzani M, Starnini M.</p>
Visual policy narrative messaging and COVID-19 vaccine uptake
<p><span>In the face of vaccine hesitancy, public health officials are seeking more effective risk communication approaches to increase vaccination rates. We test the influence of visual policy narratives on COVID-19 vaccination behavior through a panel survey experiment conducted in early 2021 (n=3900) and then eight weeks later (n=2268). We examine the effects of three visual policy narrative messages that test the narrative mechanism of character selection (<em>yourself, your circle, </em>and<em> your community</em>) and a non-narrative control on COVID-19 vaccine behavior. Visual risk messages that use narratives positively influence COVID-19 vaccination through serial mediation of affective response to the messages and motivation to get the COVID-19 vaccination. Additionally, character selection matters, as messages focusing on protecting others (i.e., <em>your</em> <em>circle</em> and <em>your</em> <em>community</em>) perform stronger than that of <em>yourself</em>. Political ideology moderated some of the effects, with conservative respondents in the non-narrative control condition having a higher probability of vaccination in comparison to the <em>protect</em> <em>yourself</em> condition. Taken together, these results suggest that public health officials should use narrative-based visual communication messages that emphasize communal benefits of vaccinations.</span></p>
Data for: Evaluation of antibody kinetics and durability in health individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): a cross-sectional and cohort study in Zhejiang, China
<p><strong>Background</strong>: Although inactivated COVID-19 vaccines are proven to be safe and effective in the general population, the dynamic response and duration of antibodies after vaccination in the real world should be further assessed.</p> <p><strong>Methods</strong>: We enrolled 1067 volunteers who had been vaccinated with one or two doses of CoronaVac in Zhejiang Province, China. Another 90 healthy adults without previous vaccinations were recruited and vaccinated with three doses of CoronaVac, 28 days and 6 months apart. Serum samples were collected from multiple timepoints and analyzed for specific IgM/IgG and neutralizing antibodies (NAbs) for immunogenicity evaluation. Antibody responses to the Delta and Omicron variants were measured by pseudovirus-based neutralization tests.</p> <p><strong>Results</strong>: Our results revealed that binding antibody IgM peaked 14–28 days after one dose of CoronaVac, while IgG and NAbs peaked approximately 1 month after the second dose and then declined slightly over time. Antibody responses had waned by month 6 after vaccination and became undetectable in the majority of individuals at 12 months. Levels of NAbs to live SARS-CoV-2 were correlated with anti-SARS-CoV-2 IgG and NAbs to pseudovirus, but not IgM. Homologous booster around 6 months after primary vaccination activated anamnestic immunity and raised NAbs 25.5-fold. The neutralized fraction subsequently rose to 36.0% for Delta (p=0.03) and 4.3% for Omicron (p=0.004), and the response rate for Omicron rose from 7.9% (7/89) to 17.8% (16/90).</p> <p><strong>Conclusions</strong>: Two doses of CoronaVac vaccine resulted in limited protection over a short duration. The inactivated vaccine booster can reverse the decrease of antibody levels to prime strain, but it does not elicit potent neutralization against Omicron; therefore, the optimization of booster procedures is vital.</p>
Effects of Covid-19 Vaccines on the Menstrual Cycle: A Cross-Sectional Study
<p>Background: Prior clinical studies that sought to investigate the safety and efficacy of Covid-19 vaccines did not list menstrual cycle changes as a side-effect. However, following reported cases of menstrual cycle disturbances after vaccination, this study sought to examine the link between Covid-19 vaccination and post-vaccine menstrual cycle abnormalities in pre- and post-menopausal women.</p> <p>Methods: A cross-sectional research design approach using online surveys was employed to investigate the link between vaccination and changes in menstrual cycle. The participants consisted of a cohort of 657 pre- and post-menopausal women with the majority drawn from the reproductive age group (25-44 years). The inclusion criteria was that participants must have received any type of Covid-19 vaccine, not be pregnant and those that did not have a negative diagnosis in any gynecologic condition. Of the eligible sample size, only 344 participants met the inclusion criteria. The sociodemographic and menstrual cycle data was collected from an online survey. Data was analyzed using descriptive, inferential chi-square tests, logistic regression, and correlation.</p> <p>Results: The results partially confirmed the findings from prior studies that Covid-19 vaccination is associated with significant changes in the women’s menstrual cycle flow and menstrual period length even after controlling for age, Body Mass Index, and ethnicity. Other menstrual cycle disturbances such as missed periods, cycle regularity, and spotting/vaginal bleeding were noted to be less significant. However, the extent of menstrual cycle changes was less severe and decreased after the second dose vaccination. It was found that 11.1% and 37.5% of post-menopausal women reported menstrual symptoms after the first and the second dose cycle respectively.</p> <p>Conclusion: The study concludes that although Covid-19 vaccines tend to adversely affect women’s menstrual cycle, these changes are short-lived. The findings have important implications in enhancing the success of Covid-19 vaccination programs by reducing cases of vaccine hesitancy among reproductive-age women.</p>
COVID-19 vaccination single cell datasets
<p>The datasets presented here comprise the sequencing data featured in the research paper titled: "Multimodal single-cell datasets characterize antigen-specific CD8<sup>+</sup> T cells across SARS-CoV-2 vaccination and infection": https://www.nature.com/articles/s41590-023-01608-9</p> <p>Peripheral Blood Mononuclear Cell (PBMC) samples utilized for both CITE-seq and ASAP-seq were systematically collected at four distinct time intervals:</p> <ul> <li>Pre-vaccination (Day 0)</li> <li>Post-primary vaccination (Day 2 and Day 10.</li> <li>Seven days post-boost vaccination (Day 28).</li> </ul> <p>The count matrix folder contains count matrices for each experimental type, specifically CITE-seq, ASAP-seq, and ECCITE-seq. In addition, we have included the fully integrated, processed Seurat objects for downstream analysis.</p> <p>Details of the content within the count matrix folder are as follows:</p> <ul> <li>The RNA, ATAC, and TCR modality outputs were generated using the 10x Cellranger pipeline.</li> <li>HTO and ADT modalities were mapped with Alevin.</li> </ul> <p>Outlined below are the three processed single-cell datasets:</p> <ol> <li>PBMC_vaccine_CITE.rds: 3' RNA and surface proteins (173 TotalSeq-A antibodies)</li> <li>PBMC_vaccine_ASAP.rds: Chromatin accessibility and surface proteins (173 TotalSeq-A antibodies)</li> <li>PBMC_vaccine_ECCITE_TCR.rds: 5' RNA, surface proteins (137 TotalSeq-C antibodies), TCR and dextramer loaded with peptides of SARS-CoV-2 spike protein.</li> </ol> <ul> <li>antigen_module_genes.rds: This file contains the vaccine-induced gene sets.</li> <li>antigen_module_peaks.rds: This file contains the DE peaks specific for vaccine-induced cells. </li> </ul> <p>To map the scRNA-seq query dataset onto our CITE-seq reference:</p> <pre><code>library(Seurat) PBMC_CITE <- readRDS("/zenedo/PBMC_vaccine_CITE.rds") query_scRNA <- readRDS("/home/xx/your_own_data.rds") anchors <- FindTransferAnchors( reference = PBMC_CITE, query = query_scRNA, normalization.method = "SCT", k.anchor = 5, reference.reduction = "spca", dims = 1:50) query_scRNA <- MapQuery( anchorset = anchors, query = query_scRNA, reference = PBMC_CITE, refdata = list( l1 = "celltypel1", l2 = "celltypel2", l3 = "celltypel3"), reference.reduction = "spca", reduction.model = "wnn.umap") </code></pre> <p>To use the scATAC-seq data, please run the commands below to update the path of the fragment file for the object. </p> <pre><code>Vaccine_ASAP <- readRDS("PBMC_vaccine_ASAP.rds") # remove fragment file information Fragments(Vaccine_ASAP) <- NULL # Update the path of the fragment file Fragments(Vaccine_ASAP) <- CreateFragmentObject(path = "download/PBMC_vaccine_ASAP_fragments.tsv.gz", cells = Cells(Vaccine_ASAP))</code></pre> <p> </p>
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
ClinicalTrials.gov study NCT04380701. IPD Sharing: NO. Countries: 1. Publications: 10.
Views on COVID-19 and Vaccination
ClinicalTrials.gov study NCT04706403. IPD Sharing: NO. Countries: 1. Publications: 6.
Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
ClinicalTrials.gov study NCT05028361. IPD Sharing: NO. Countries: 1. Publications: 2.
Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults
ClinicalTrials.gov study NCT04313127. IPD Sharing: YES. Countries: 1. Publications: 1.
Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant
ClinicalTrials.gov study NCT05124509. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers
ClinicalTrials.gov study NCT05148962. IPD Sharing: NO. Countries: 1. Publications: 1.
COVID-19 Vaccine Uptake Trial
ClinicalTrials.gov study NCT05419232. IPD Sharing: NO. Countries: 1. Publications: 7.
Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination
ClinicalTrials.gov study NCT04904744. IPD Sharing: NO. Countries: 1. Publications: 1.
COVID-19 Vaccine Boosters in Patients With CKD
ClinicalTrials.gov study NCT05022329. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Tableted COVID-19 Therapeutic Vaccine
ClinicalTrials.gov study NCT04380532. IPD Sharing: YES. Countries: 2. Publications: 1.
Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain
ClinicalTrials.gov study NCT04993560. IPD Sharing: YES. Countries: 1. Publications: 10.
Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects
ClinicalTrials.gov study NCT04671017. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
ClinicalTrials.gov study NCT04649151. IPD Sharing: Not stated. Countries: 2. Publications: 2.
COVID-19 Vaccine Response in Sickle Cell Disease
ClinicalTrials.gov study NCT05139992. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.